JP2022531556A5 - - Google Patents
Info
- Publication number
- JP2022531556A5 JP2022531556A5 JP2021562803A JP2021562803A JP2022531556A5 JP 2022531556 A5 JP2022531556 A5 JP 2022531556A5 JP 2021562803 A JP2021562803 A JP 2021562803A JP 2021562803 A JP2021562803 A JP 2021562803A JP 2022531556 A5 JP2022531556 A5 JP 2022531556A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- nucleic acid
- seq
- acid molecule
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2019/061134 WO2020221450A1 (en) | 2019-04-30 | 2019-04-30 | Antibodies and methods for treatment of influenza a infection |
| EPPCT/EP2019/061134 | 2019-04-30 | ||
| PCT/EP2020/062160 WO2020221908A1 (en) | 2019-04-30 | 2020-04-30 | Antibodies and methods for treatment of influenza a infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022531556A JP2022531556A (ja) | 2022-07-07 |
| JP2022531556A5 true JP2022531556A5 (https=) | 2023-05-02 |
| JP7719725B2 JP7719725B2 (ja) | 2025-08-06 |
Family
ID=66429359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562803A Active JP7719725B2 (ja) | 2019-04-30 | 2020-04-30 | Ａ型インフルエンザ感染の抗体及び治療法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220226470A1 (https=) |
| EP (1) | EP3962530A1 (https=) |
| JP (1) | JP7719725B2 (https=) |
| KR (1) | KR20220003000A (https=) |
| CN (2) | CN119192357A (https=) |
| AU (1) | AU2020265407B2 (https=) |
| BR (1) | BR112021018409A2 (https=) |
| CA (1) | CA3132536A1 (https=) |
| CL (1) | CL2021002807A1 (https=) |
| CO (1) | CO2021012583A2 (https=) |
| EA (1) | EA202192923A1 (https=) |
| IL (1) | IL287423A (https=) |
| MX (1) | MX2021012984A (https=) |
| PH (1) | PH12021552176A1 (https=) |
| SG (1) | SG11202109683TA (https=) |
| TW (1) | TW202106707A (https=) |
| WO (2) | WO2020221450A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11780907B2 (en) | 2018-01-26 | 2023-10-10 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
| IL290752B2 (en) * | 2019-08-29 | 2026-02-01 | Vir Biotechnology Inc | Preparations and methods for treating influenza a infection |
| AR124266A1 (es) * | 2020-12-08 | 2023-03-01 | Vir Biotechnology Inc | Anticuerpos y métodos para el tratamiento de infección por gripe a |
| CN112812095A (zh) * | 2021-01-29 | 2021-05-18 | 成都安满生物医药科技有限公司 | 一种巴洛沙韦酯中间体的合成方法 |
| WO2023201306A1 (en) | 2022-04-14 | 2023-10-19 | Invisishield Technologies Ltd. | Compositions for preventing or treating influenza infections |
| CN115777944B (zh) * | 2023-02-10 | 2023-05-12 | 北京衡美金叶营养健康科技有限公司 | 增强身体防御力的组合物及其制备方法和应用 |
| WO2025024541A2 (en) * | 2023-07-24 | 2025-01-30 | University Of Miami | Aav-delivered antibodies and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PL2350128T3 (pl) | 2008-10-22 | 2015-03-31 | Inst Res Biomedicine | Sposoby wytwarzania przeciwciał z komórek plazmatycznych |
| US8326547B2 (en) | 2009-10-07 | 2012-12-04 | Nanjingjinsirui Science & Technology Biology Corp. | Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm |
| US8637024B2 (en) | 2010-11-12 | 2014-01-28 | The Rockefeller University | Fusion antibodies for HIV therapy |
| WO2014087299A1 (en) | 2012-12-07 | 2014-06-12 | Pfizer Inc. | Engineered monomeric antibody fragments |
| SI3052192T1 (sl) * | 2013-10-02 | 2020-11-30 | Medimmune, Llc | Nevtralizarijoča protitelesa proti-influenci A in njihove uporabe |
| SG11201805001UA (en) | 2016-01-13 | 2018-07-30 | Medimmune Llc | Method of treating influenza a |
-
2019
- 2019-04-30 WO PCT/EP2019/061134 patent/WO2020221450A1/en not_active Ceased
-
2020
- 2020-03-04 TW TW109107093A patent/TW202106707A/zh unknown
- 2020-04-30 PH PH1/2021/552176A patent/PH12021552176A1/en unknown
- 2020-04-30 MX MX2021012984A patent/MX2021012984A/es unknown
- 2020-04-30 JP JP2021562803A patent/JP7719725B2/ja active Active
- 2020-04-30 WO PCT/EP2020/062160 patent/WO2020221908A1/en not_active Ceased
- 2020-04-30 CN CN202411518877.XA patent/CN119192357A/zh active Pending
- 2020-04-30 AU AU2020265407A patent/AU2020265407B2/en active Active
- 2020-04-30 BR BR112021018409A patent/BR112021018409A2/pt unknown
- 2020-04-30 EP EP20721638.3A patent/EP3962530A1/en active Pending
- 2020-04-30 US US17/607,383 patent/US20220226470A1/en active Pending
- 2020-04-30 KR KR1020217038260A patent/KR20220003000A/ko active Pending
- 2020-04-30 CA CA3132536A patent/CA3132536A1/en active Pending
- 2020-04-30 SG SG11202109683TA patent/SG11202109683TA/en unknown
- 2020-04-30 EA EA202192923A patent/EA202192923A1/ru unknown
- 2020-04-30 CN CN202080034142.3A patent/CN114269381A/zh active Pending
-
2021
- 2021-09-24 CO CONC2021/0012583A patent/CO2021012583A2/es unknown
- 2021-10-20 IL IL287423A patent/IL287423A/en unknown
- 2021-10-26 CL CL2021002807A patent/CL2021002807A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531556A5 (https=) | ||
| EP3261720B1 (en) | Antibodies to tau and uses thereof | |
| JP2019511911A5 (https=) | ||
| AU2016334290B2 (en) | Antibody to hepatitis B surface antigen and use thereof | |
| CN108064240A (zh) | 针对流感血凝素的人抗体 | |
| JP2018535650A5 (https=) | ||
| JP6162319B2 (ja) | ヒト化抗ｎ２抗体 | |
| JP2017500018A5 (https=) | ||
| CN101952454A (zh) | 具有减弱的Fc配体亲和性的抗IFNAR1抗体 | |
| JP2023505492A5 (https=) | ||
| JP2021534797A5 (https=) | ||
| JPWO2020059847A5 (https=) | ||
| JP2017523805A5 (https=) | ||
| EP4705338A1 (en) | Methods of administering antibodies that bind interleukin 13 | |
| EP4423123A1 (en) | Engineered fc variants | |
| JPWO2022044573A5 (https=) | ||
| TW202221025A (zh) | 用於治療和預防ｃｏｖｉｄ—１９的ｓａｒｓ—ｃｏｖ—２抗體 | |
| JP2022531552A5 (https=) | ||
| JP2024524895A5 (https=) | ||
| JP2025522295A5 (https=) | ||
| JP2025519612A (ja) | Ｉｇｆ１ｒ抗体 | |
| CN115515978A (zh) | 用于治疗呼吸系统疾病的pan-elr+cxc趋化因子抗体 | |
| WO2025218746A1 (en) | Methods of treating rheumatoid arthritis | |
| JP2022553703A (ja) | 抗血球凝集素抗体およびその使用方法 | |
| WO2022140659A2 (en) | Anti-cd47 antibodies and uses thereof |